Slide 1: Topline CLARITY Results Phase 3 Clinical Trials
NASDAQ: LENZ Topline CLARITY Results Phase 3 Clinical Trials April 3rd 2024
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words suc
Slide 3: LNZ100: potential best-in-class performance and selected as commercial candidate
3 LNZ100: potential best-in-class performance and selected as commercial candidate for mid-2024 NDA submission All data refers to LNZ100 CLARITY 2 – Vehicle Controlled, day 1 results unless otherwise specified; 1. Across CLARITY 1 & 2 Efficacy Trials; 2. Across all CLARITY Trials Exclusive aceclidin
Slide 4: CLARITY Study Design
4 CLARITY 1 and 2 Study Design Randomized, double masked, controlled, Phase 3 trials (NCT05656027 & NCT05728944) 25 sites participated in CLARITY 1, and 17 sites participated in CLARITY 2 Ages 45 – 75, Mean 55 years Refractive range -4D SE to +1D SE Inclusive of post-LASIK presbyopes and pseudophake
Slide 5: LNZ100 achieved rapid onset and 10 hours duration
5 LNZ100 achieved rapid onset and 10 hours duration % of Participants Achieving ≥3-Line Near Vision Improvement (no loss of 1 line or more BCDVA) P e rc e n ta g e ( % ) CLARITY 2, day 1 results, full analysis set. Near visual acuity was assessed at 40cm using Monocular BCDVA (best-corrected distanc
Slide 6: Nearly all participants (95%) achieved a ≥2-Line improvement
6 Nearly all participants (95%) achieved a ≥2-Line improvement % of Participants Achieving ≥2-Line Near Vision Improvement (no loss of 1 line or more BCDVA) P e rc e n ta g e ( % ) CLARITY 2, day 1 results, full analysis set. Near visual acuity was assessed at 40cm using Monocular BCDVA (best-correc
Slide 7: Positive impact to distance vision in normal light
7 Positive impact to distance vision in normal light Mean Impact to Distance Vision Over Time Best Corrected Distance Visual Acuity Le tt e rs CLARITY 2, day 1 results, full analysis set, n=77 for LNZ100 and n=76 for LNZ101. Distance visual acuity was assessed at 4m and 0.5h, 1h, 3h, 5h, 7h, 8h, 9h
Slide 8: Consistent near vision improvement over 28 days
8 71 71 40 12 8 5 81 78 11 7 82 78 35 17 9 7 0.5h 3h 10h LNZ100 Vehicle Consistent near vision improvement over 28 days % of Participants Achieving ≥3-Line Near Vision Improvement (no loss of 1 line or more BCDVA) P e rc e n ta g e ( % ) CLARITY 2, Based on full analysis set. Near visual acuity was
Slide 9: Well tolerated with vast majority of AEs reported as mild
9 Well tolerated with vast majority of AEs reported as mild Pooled analysis of CLARITY 1 & 2 List contains all AEs over 5%, 1 general most common descriptor used by participants LNZ100 N=234 n(%) Vehicle N=76 n(%) Ocular AEs Instillation site irritation (mild stinging upon instillation)1 47 (20.1%)
Slide 10: Patient satisfaction confirms commercial opportunity for 128M US presbyopes
10 Patient satisfaction confirms commercial opportunity for the vast majority of 128M US presbyopes Pooled responses of LNZ100 in Clarity 1 & 2 on day 28, n=223. Based on patient questionnaire “Reflecting on the last 30 days…” “Have you noticed an improvement in your near vision/ability to see up cl
Slide 11: 30,000+ days on LNZ100 without treatment related serious AEs
11 Across all CLARITY trials 378 participants for a combined 30,000+ days on LNZ100 without treatment related serious AEs 1. CLARITY 1 & 2 25 sites participated in CLARITY 1, 17 sites participated in CLARITY 2 and 40 sites participated in CLARITY 3 LNZ100 (1.75% aceclidine) – CLARITY 3 Day 1 Day 42
Slide 12: LNZ100 consistent performance across CLARITY 1 & 2
12 LNZ100 consistent performance across CLARITY 1 & 2; LNZ101 showed similar but not superior efficacy Day 1 Based on full analysis set. Near visual acuity was assessed at 40cm. Monocular BCDVA (best-corrected distance visual acuity) CLARITY 1 CLARITY 2 LNZ100 LNZ101 Brimonidine LNZ100 LNZ101 Vehicl
Slide 13: Additional CLARITY data to be provided at upcoming industry conferences
13 Additional CLARITY data to be provided at upcoming industry conferences Visit: LENZ-tx.com for more information